ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiRâ„¢ Trial for Myotonic Dystrophy Type 1 (DM1)

-ATX-01 is the industry’s first anti-microRNA therapeutic to be investigated in DM1 – VALENCIA, Spain, Oct. 18, 2024 /PRNewswire/ — ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced…